Q2 2026 saw 20% revenue growth to $103.5M, driven by strong test volume increases, especially for TissueCypher and DecisionDx-Melanoma. Guidance for 2026 revenue was raised to $365–$375M, with positive adjusted EBITDA expected for the remainder of 2026.Based on Castle Biosciences, Inc. [CSTL] Q2 20…
Q2 2026 saw 20% revenue growth to $103.5M, driven by strong test volume increases, especially for TissueCypher and DecisionDx-Melanoma. Guidance for 2026 revenue was raised to $365–$375M, with positive adjusted EBITDA expected for the remainder of 2026.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
